These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Relationship between estrogen receptors, 17 beta-hydroxysteroid dehydrogenase and estrogen content in human breast cancer.
    Author: Abul-Hajj YJ.
    Journal: Steroids; 1979 Aug; 34(2):217-25. PubMed ID: 494363.
    Abstract:
    Estrone and estradiol levels in tumor tissue cytosols were determined in 11 premenopausal and 20 postmenopausal women at the same time that 17 beta-hydroxysteroid dehydrogenase and estrogen receptors (ER) were carried out on their breast cancers. Estrogen receptor positive tumors showed significantly higher levels of estrone and estradiol. However, all ER negative tumors contained measurable amounts of both estradiol and estrone. Higher levels of estrone were observed in ER negative tumors which correlates well with high 17 beta-hydroxysteroid dehydrogenase activity. These results suggest that false negative receptor assays in the premenopausal women is not likely to be due to occupancy of receptors by endogenous estrogens. Furthermore, the higher estrone content in the ER negative group is probably due to high 17 beta-hydroxysteroid dehydrogenase activity inherent to these tumor cells. Studies show that premenopausal women have much lower levels of available cytoplasmic estrogen receptors than postmenopausal women. This study evaluates the levels of estradiol and estrone in tumor tissue cytosols of 11 premenopausal and 20 postmenopausal women, and relates these to estrogen receptors and 17B-hydroxysteroid dehydrogenase activity of the tumor samples. Estrone and estradiol levels were measured using highly specific antiestrodiol and antiestrone antisera supplied by the National Institutes of Health. The results show that tumor cytosol estradiol content is significantly higher in the premenopausal group than in the postmenopausal group. Endogenous tumor estrone, however, did not differ significantly in the pre-and postmenopausal groups. Higher levels of estradiol were noted in the ER (estrogen receptor)+premenopausal than in the ER- premenopausal patients. Significant lower levels were observed in the ER-postmenopausal than the ER+postmenopausal patients. These differences may be due in part to the tight binding of estradiol in ER+premenopausal group and the high 17B-hydroxysteroid dehydrogenase activity in the ER-postmenopausal tumors. These findings indicate that false negative results of assays in the premenopausal women is not related to the saturation of receptor sites by endogenous estrogens. Although the role of high levels of 17B-hydroxysteroid dehydrogenase in ER negative tumor is not clear, this enzyme, along with other steroid metabolizing enzymes, may be useful in controlling active steroids which affect the pathogenesis of mammary tumors.
    [Abstract] [Full Text] [Related] [New Search]